RNA-seq
Genialis, Debiopharm Extend Cancer Biomarker Collaboration
The companies extended a deal to develop biomarkers predictive of the clinical benefit of Debiopharm's cancer drug candidates.
Scipher Medicine, Roivant Partner on Rheumatology Drug Discovery
Roivant will integrate data derived from the development and commercialization of Scipher's PrismRA molecular test to inform its drug development pipeline.
Tempus, Genialis Partner to Develop RNA-Based Cancer Biomarker Algorithms
Genialis will use Tempus' multimodal dataset to develop new RNA-based algorithms for a variety of cancers.
In a small validation set, the model was able to make accurate predictions about patient outcomes using routinely collected patient data.
Merus Nabs FDA Accelerated Approval for Bizengri in NRG1 Fusion-Positive NSCLC, Pancreatic Cancer
The approval is based on overall response rates from the Phase II eNRGy study, which enrolled advanced, previously treated NRG1 fusion-positive patients.
Nov 22, 2024
May 21, 2024
Mar 12, 2024